Emeline Ragonnaud - Search Results

Year	Number of Results
2013	1
2015	1
2016	2
2017	2
2018	1
2019	2
2020	1
2021	2

1

Cancer Associated Endogenous Retroviruses: Ideal Immune Targets for Adenovirus-Based Immunotherapy.

Vergara Bermejo A, Ragonnaud E, Daradoumis J, Holst P. Vergara Bermejo A, et al. Among authors: ragonnaud e. Int J Mol Sci. 2020 Jul 8;21(14):4843. doi: 10.3390/ijms21144843. Int J Mol Sci. 2020. PMID: 32650622 Free PMC article. Review.

2

Gut microbiota as the key controllers of "healthy" aging of elderly people.

Ragonnaud E, Biragyn A. Ragonnaud E, et al. Immun Ageing. 2021 Jan 5;18(1):2. doi: 10.1186/s12979-020-00213-w. Immun Ageing. 2021. PMID: 33397404 Free PMC article. Review.

3

Tumor-Derived Thymic Stromal Lymphopoietin Expands Bone Marrow B-cell Precursors in Circulation to Support Metastasis.

Ragonnaud E, Moritoh K, Bodogai M, Gusev F, Garaud S, Chen C, Wang X, Baljinnyam T, Becker KG, Maul RW, Willard-Gallo K, Rogaev E, Biragyn A. Ragonnaud E, et al. Cancer Res. 2019 Nov 15;79(22):5826-5838. doi: 10.1158/0008-5472.CAN-19-1058. Epub 2019 Oct 1. Cancer Res. 2019. PMID: 31575547 Free PMC article.

4

CD8+ T cells induced by adenovirus-vectored vaccine are capable of preventing establishment of latent murine γ-herpesvirus 68 infection.

Boilesen DR, Ragonnaud E, Laursen H, Andersson AC, Tolver A, Spiess K, Holst PJ. Boilesen DR, et al. Among authors: ragonnaud e. Vaccine. 2019 May 16;37(22):2952-2959. doi: 10.1016/j.vaccine.2019.04.034. Epub 2019 Apr 18. Vaccine. 2019. PMID: 31006497

5

Therapeutic Vaccine Against Primate Papillomavirus Infections of the Cervix.

Ragonnaud E, Andersson AC, Mariya S, Pedersen AG, Burk RD, Folgori A, Colloca S, Cortese R, Nicosia A, Pamungkas J, Iskandriati D, Holst PJ. Ragonnaud E, et al. J Immunother. 2017 Feb/Mar;40(2):51-61. doi: 10.1097/CJI.0000000000000153. J Immunother. 2017. PMID: 28166180

6

Replication deficient human adenovirus vector serotype 19a/64: Immunogenicity in mice and female cynomolgus macaques.

Ragonnaud E, Schroedel S, Mariya S, Iskandriati D, Pamungkas J, Fougeroux C, Daradoumis J, Thomsen AR, Neukirch L, Ruzsics Z, Salomon M, Thirion C, Holst PJ. Ragonnaud E, et al. Vaccine. 2018 Oct 1;36(41):6212-6222. doi: 10.1016/j.vaccine.2018.07.075. Epub 2018 Sep 3. Vaccine. 2018. PMID: 30190120

7

Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Andersson AC, Ragonnaud E, Seaton KE, Sawant S, Folgori A, Colloca S, Labranche C, Montefiori DC, Tomaras GD, Holst PJ. Andersson AC, et al. Among authors: ragonnaud e. Vaccine. 2016 Oct 17;34(44):5344-5351. doi: 10.1016/j.vaccine.2016.08.089. Epub 2016 Sep 12. Vaccine. 2016. PMID: 27633665 Free PMC article.

8

The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Ragonnaud E, Holst P. Ragonnaud E, et al. Ther Adv Vaccines. 2013 May;1(1):33-47. doi: 10.1177/2051013613480446. Ther Adv Vaccines. 2013. PMID: 24757514 Free PMC article.

9

Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection.

Holst PJ, Jensen BA, Ragonnaud E, Thomsen AR, Christensen JP. Holst PJ, et al. Among authors: ragonnaud e. PLoS One. 2015 Feb 13;10(2):e0117242. doi: 10.1371/journal.pone.0117242. eCollection 2015. PLoS One. 2015. PMID: 25679375 Free PMC article.

10

An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.

Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. Ragonnaud E, et al. Vaccine. 2016 Apr 19;34(18):2147-56. doi: 10.1016/j.vaccine.2015.06.087. Epub 2016 Mar 19. Vaccine. 2016. PMID: 27004934

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results